Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Cladribine (2-chloro-2′-deoxyadenosine) is an adenosine deaminase-resistant analogue of deoxyadenosine. In the treatment of hairy cell leukaemia, cladribine has demonstrated excellent efficacy (complete response in 33 to 92% of patients) in noncomparative studies. Cladribine appears to compare favourably with other systemic agents in this indication as it achieves a high degree of efficacy after a single 7-day course, with an acceptable tolerability profile. However, long term data and direct comparative studies with interferon-α and pentostatin (deoxycoformycin) are required to confirm the finite advantages offered by cladribine.
Preliminary results obtained in other indications including chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma, cutaneous T cell lymphoma, Waldenström’s macroglobinaemia and acute myeloid leukaemia in children have been sufficiently encouraging to warrant further study. Early pharmacokinetic data suggest that cladribine may be administered by oral and subcutaneous routes, both of which permit convenient outpatient therapy.
Myelosuppression, the dose-limiting toxicity of cladribine, and culture-negativ e fever are the most common adverse effects associated with therapy. However, cladribine appears to be only rarely associated with many of the other adverse effects that characterise antineoplastic therapy. In the weeks post-treatment, there is a small but definite risk of serious infection; infections with a fatal outcome have been reported in a number of studies with cladribine.
In conclusion, preliminary data concerning cladribine have been extremely encouraging. Should early response rates in patients with hairy cell leukaemia be sustained, the efficacy of the drug, together with a short treatment regimen, a favourable tolerability profile, and the possibility of oral therapy, suggest that cladribine is likely to supersede other agents available for this indication.
Cladribine is an adenosine deaminase (ADA)-resistant analogue of deoxyadenosine. The drug has a broad range of in vitro activity against both lymphoid and myeloid neoplasms [mean IC50 values (drug concentration required to inhibit cell growth by 50% of control) 20 to 87 nmol/L], but possesses little activity against multiple myeloma specimens and many solid tumour cell lines. Monocytes are highly sensitive to cladribine in vitro. Cladribine demonstrates activity against both dividing and nondividing cells, activity that distinguishes it from many other agents, and also has activity in murine models of leukaemia.
The precise mechanism of action of cladribine in either dividing or nondividing cells is unknown. Incorporation of the triphosphate form of cladribine into DNA is thought to be important in arresting cell activity. Cladribine is a potent inhibitor of ribonuclease reductase (IC50 0.11 to 0.28 μmol/L), which also may be involved in its activity. In nondividing cells, it has been suggested that cladribine may induce apoptosis (programmed cell death).
After a 2-hour intravenous infusion of cladribine 0.14 mg/kg/day, the mean maximum plasma drug concentration was 198 nmol/L. Intracellular concentrations of phosphorylated cladribine derivatives exceed plasma concentrations 128- to 375-fold. Cladribine penetrates into the CSF. The terminal elimination half-life (6.7 hours) is long, which suggests that the drug may be administered intermittently without loss of efficacy. The volume of distribution of cladribine is 9.2 L/kg.
Cladribine has also been administered successfully by both oral and subcutaneous routes; after oral administration in buffer solution, systemic bioavailability was 55%.
All trials conducted with cladribine to date have been noncomparative in nature and conducted in relatively small numbers of patients. The majority of studies involved the recommended 7-day regimen of intravenous cladribine 0.1 mg/kg/day, administered as a continuous infusion.
The best and most durable response with cladribine has been obtained in patients with hairy cell leukaemia. A complete response was achieved in 33 to 92%, and a partial or complete response in 67 to 100%, of a total of 298 evaluable patients involved in 8 clinical trials. Three relapses only were reported after a median follow-up of 20 to 76 weeks. Previous therapy with splenectomy, interferon-α or a combination of the 2 treatment modalities did not appear to affect the response rate to cladribine.
Cladribine is also being investigated as a second-line agent in chronic lymphocytic leukaemia (CLL). An overall response rate of 44% (4% complete response) was achieved after a median of 2 courses of cladribine therapy in 90 patients with refractory CLL. The median duration of response was 4 months. While some investigators have reported good results in patients with CLL resistant to fludarabine, more recent data have been less encouraging. Given the marked immunosuppression associated with the use of nucleoside analogues, cladribine should be used with caution after fludarabine has failed.
In a total of 73 patients with refractory low- or intermediate-grade non-Hodgkin’s lymphoma, 43 to 50% responded for a median duration of 5 to 6 months to cladribine administered as salvage therapy, 8 to 20% of whom achieved a complete response.
Encouraging results have also been reported in paediatric patients with refractory acute myelogenous leukaemia (AML). Eight of 17 (47%) patients with AML achieved a complete response after treatment with cladribine 8.9 mg/m2/day administered for 5 days; a further 2 patients had a partial remission giving an overall response rate of 59%. A poorer response was achieved in adults with AML and in patients with acute lymphoblastic leukaemia.
In smaller groups of patients, cladribine has also demonstrated efficacy in cutaneous T cell lymphoma, Waldenström’s macroglobinaemia, autoimmune haemolytic anaemia, prolymphocytic leukaemia, and some activity in chronic myeloid leukaemia.
Unlike other antineoplastic agents, cladribine is rarely associated with nausea, vomiting, alopecia, skin rash, or abnormal renal or hepatic function when administered at the recommended dosage. The dose-limiting toxicity of cladribine is bone marrow suppression. In general, myelosuppression is manifested as reversible neutropenia, anaemia and thrombocytopenia after a standard course of cladribine therapy. There have been only isolated reports of pancytopenia. In common with both pentostatin (deoxycoformycin) and fludarabine, cladribine suppresses lymphocytes expressing CD4 or CD8 surface antigens.
Another common adverse effect associated with cladribine is culture-negative fever, which affects 46 to 58% of patients with hairy cell leukaemia. There is a small but definite risk of opportunistic infections in the post-treatment period. Infections have been reported in 10 to 39% of cladribine-treated patients. Serious infections with a fatal outcome have been described in a number of studies.
Dosage and Administration
The recommended regimen for cladribine in hairy cell leukaemia is a single continuous 7-day intravenous infusion at a dosage of 0.09 mg/kg/day (corrected for extinction coefficient). The dosage used in the majority of clinical trials (0.1 mg/kg/day) was standardised originally using the extinction coefficient of chloroadenine which is lower than that of cladribine. Thus, the actual cladribine dose administered was about 87% of that stated; the corrected dosage of cladribine is therefore 0.09 mg/kg/day.
A second course of therapy has been administered in patients who relapse in some trials. The same regimen administered monthly for up to 6 courses can be used to treat patients with CLL, low-grade lymphoma or cutaneous T cell lymphoma resistant to other agents. Antibiotic support should be administered as required. In children with acute myelogenous leukaemia, the recommended maximum tolerated dosage is 8.9 mg/m2/day administered as a 5-day continuous infusion. Caution is required when administering cladribine after or in combination with agents known to cause myelosuppression.
- Albertioni F, Juliusson G, Liliemark J. On the bioavailability of 2-chloro-2′-deoxyadenosine (CdA): the influence of food and omeprazole. European Journal of Clinical Pharmacology 44:579–582, 1993 CrossRef
- Ames MM, Bagniewski PG, Reid JM, Richardson RL, Marks RS, et al. Clinical and pharmacokinetic evaluation of 2-chloro-deoxy-adenosine: results from three phase I clinical trials. Abstract no. 2352, p. 394. Proceedings of the American Association for Cancer Research Vol. 134, 1993
- Anonymous. Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. Editorial. Leukemia 1: 405, 1987
- Anonymous. Cladribine prescribing information, USA, 1993
- Armitage JO. Treatment of non-Hodgkin’s lymphoma. New England Journal of Medicine 328: 1023–1030, 1993 CrossRef
- Avery TL, Rehg JE, Lumm WC, Harwood FC, Santana VM, et al. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Research 49: 4972–4978, 1989
- Barton K, Larson RA, O’Brien S, Ratain MJ. Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine. Letter. Journal of Clinical Oncology 10: 1821, 1992
- Beutier E, Piro LD, Saven A, Kay AC, McMillan R, et al. 2-Chlorodeoxyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leukemia and Lymphoma 5: 1–8, 1991 CrossRef
- Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340: 952–956, 1992 CrossRef
- Brogden RN, Sorkin EM. Pentostatin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in lymphoproliferative disorders. Drugs 46: 652–677, 1993 CrossRef
- Carrera CJ, Piro LD, Miller WE, Carson DA, Beutler E. Remission induction in hairy cell leukemia by treatment with 2-chlorodeoxyadenosine: role of DNA strand breaks and NAD depletion. Abstract. Clinical Research 35: 597A, 1987
- Carrera CJ, Yamanaka H, Piro LD, Lotz M, Carson DA. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitro and ex vivo. Advances in Experimental Medicine and Biology 253b: 219–225, 1989 CrossRef
- Carrera CJ, Terai C, Lotz M, Curd JG, Piro LD, et al. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy. Journal of Clinical Investigation 86: 1480–1488, 1990
- Carson DA, Wasson DB, Kaye J, Ullman B, Martin Jr DW, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proceeding of the National Academy of Sciences of the United States of America 77: 6865–6869, 1980 CrossRef
- Carson DA, Wasson DB, Lakow E, Kamatani N. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proceedings of the National Academy of Sciences of the United States of America 79: 3848–3852, 1982a CrossRef
- Carson DA, Wasson DB, Lamon J, Beutler E. A potent new anti-lymphocyte agent: 2-chlorodeoxyadenosine. Abstract no. 568. Blood 60 (Suppl. 1): 160a, 1982b
- Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62: 737–743, 1983
- Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2’deoxyadenosine. Proceedings of the National Academy of Sciences of the United States of America 81:2232–2236, 1984 CrossRef
- Carson DA, Wasson DB, Yu A. Cell cycle independent lymphotoxicity of 2-chlorodeoxyadenosine. Advances in Experimental Medicine and Biology 165B: 351–356, 1984
- Carson DA, Carrera CJ, Wasson DB, Yamanaka H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Advances in Enzyme Regulation 27: 395–404, 1988a CrossRef
- Carson DA, Piro LD, Wasson DB, Carrera CJ, Beutler E. Potent activity of 2-chlorodeoxyadenosine in chronic lymphocytic leukemia, hairy cell leukemia, and autoimmune hemolytic anemia. Abstract. Pediatric Research 24: 114, 1988b
- Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps TJ, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2’arabino-fluoro-2’ -deoxyadenosine. Proceedings of the National Academy of Sciences of the United States of America 89: 2970–2974, 1992 CrossRef
- Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 341: 1251–1254, 1993 CrossRef
- Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. American Journal of Hematology 29: 152–163, 1988 CrossRef
- Cheson BD. Chronic lymphocytic leukemia and hairy-cell leukemia. Current Opinion in Oncology 3: 54–62, 1991 CrossRef
- Christensen LF, Broom AD, Robins MJ, Bloch A. Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy-α- and β-D-erythro-pentofuranosyl)purines. Journal of Medicinal Chemistry 15: 735–739, 1972 CrossRef
- Chunduru SK, Appleman JR, Blakely RL. Activity of human DNA polymerases α and β with 2-chloro-2′-deoxyadenosine 5′-triphosphate as a substrate and quantitative effects of incorporation on chain extension. Archives of Biochemistry and Biophysics 302: 19–30, 1993 CrossRef
- Damasio Ambrosetti A, Brugiatelli M, Cabras G, Capnist G, et al. Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (2-CdA). Abstract. 34th Congresso Societa’ Italiana di Ematologia, Naples, Italy, October 5–8, 1993
- Dann EJ, Getlis S, Polliack A, et al. New England Journal of Medicine, In press, 1993
- Delannoy A, Hanique G, Ferrant A. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. Letter. New England Journal of Medicine 328: 812, 1993 CrossRef
- Dimopoulos MA, Kantarjian HM, Estey EH, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. Letter. Blood 80: 1626, 1992
- Dimopoulos MA, Kantarjian H, Estey EH, Alexanian R. Response. Blood 81: 868–869, 1993a
- Dimopoulos ME, Kantarjian H, Estey E, O’Brien S, Delasalle K, et al. Treatment of Waidenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Annals of Internal Medicine 118: 195–198, 1993b
- Estey EH, Kurzrock R, Kantarjian HM, O’Brien SM, McCredie KB, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79: 882–887, 1992
- Figueroa M, McMillan R. 2-Chlorodeoxyadenosine in the treatment of chronic refractory immune thrombocytopenic purpura. Blood 81: 3484–3485, 1993
- Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights into biology and therapy. Annals of Internal Medicine 113: 525–539, 1990
- Giblett ER, Anderson JE, Cohen F, Pollara Meuwisson HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067–1069, 1972 CrossRef
- Golomb HM, Ellis E. Treatment options for hairy-cell leukemia. Seminars in Oncology 18 (Suppl. 7): 7–11, 1991
- Golomb HM, Ratain MJ, Mick R, Daly K. The treatment of hairy cell leukemia: an update. Leukemia 6 (Suppl. 2): 24–27, 1992
- Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Research 49: 6923–6928, 1989
- Hakimian D, Tallman MS, Kiely C, Peterson L. Immunophenotypic analysis of bone marrow core biopsies before and after 2-chlorodeoxyadenosine treatment for hairy cell leukemia. Abstract no. 840. Blood 80 (Suppl. 1): 212a, 1992
- Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2′-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases α and β. Journal of Biological Chemistry 265: 4033–4040, 1990
- Hickish T, Serafinowski P, Cunningham D, Oza A, Dorland E, et al. 2′-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. British Journal of Cancer 67: 139–143, 1993 CrossRef
- Hirota Y, Yoshioka A, Tanaka S, Watanbe K, Otani T, et al. Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells. Cancer Research 49: 915–919, 1989
- Hoffman M, Rai KR, Janson D, Kubik B, Calabrese A, et al. Comparison of complete remission (CR) rates among previously treated or untreated hairy cell leukemia (HCL) patients (PTS) with 2-chlorodeoxyadenosine (CdA). 28th Annual Meeting of the American Society of Clinical Oncology, San Diego, May 17–19, 1992. Abstract no. 895. Proceedings of the American Society of Clinical Oncology, 1992
- Hoffman M, Rai KR, Janson D. Follow-up of patients with hairy cell leukemia (HCL) and non-Hodgkins Lymphoma (NHL) treated at Long Island Jewish Medical Center (LIJMC) with 2′chlorodeoxyadenosine (2 CdA). 8th Symposium Molecular Biology of Haematopoiesis, Basel, July 9–13, 1993. Abstract, p. 161, 1993
- Huang M-C, Ashmun RA, Avery TL, Kuehl M, Blakley RL. Effects of cytotoxicity of 2-chloro-2′-deoxyadenosine and 2-bromo-2′-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics. Cancer Research 46: 2362–2368, 1986
- Hurwitz CA, Krance R, Schell MJ, Santana VM, Brenner MK, et al. Current strategies for treatment of acute myeloid leukemia at St Jude Children’s Research Hospital. Leukemia 6 (Suppl. 2): 39–43, 1992
- Juliusson G, Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood 79: 888–894, 1992
- Juliusson G, Liliemark J, Hippe E, Blichfeldt P, Wallman K, et al. Subcutaneous injections of 2-chloro-2′-deoxyadenosine (CdA) as treatment for symptomatic hairy cell leukemia (HCL). Abstract no. 1427. Blood 80 (Suppl. 1): 359a, 1992a
- Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with -cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine 327: 1056–1061, 1992b CrossRef
- Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. Journal of Clinical Oncology 11:679–689, 1993a
- Juliusson G, Liliemark J. Complete remission of B-cell chronic lymphocytic leukaemia after oral cladribine. Letter. Lancet 341: 54, 1993b CrossRef
- Juliusson G, Liliemark J. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. Letter. New England Journal of Medicine 328: 813, 1993c CrossRef
- Kahn J, Kaplan L, Northfelt D, Piro L, Beutier E, et al. 2-Chlorodeoxyadenosine (2-CDA) for AIDS-associated non-Hodgkin’s lymphoma (NHL). A phase I study. 27th Annual Meeting of the American Society of Clinical Oncology, Houston, May 12–14, 1991. Abstract no. 12, p. 34. Proceedings of the American Society of Clinical Oncology, 1991
- Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, et al. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. Journal of Clinical Oncology 10: 371–377, 1992
- Keating MJ, O’Brien S, Robertson L, Plunkett W, Kantarjian H, et al. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia 6 (Suppl. 4): 140–141, 1992
- Keating MJ. Chronic lymphoproliferative disorders: chronic lymphocytic leukemia and hairy-cell leukemia. Current Opinion in Oncology 5: 35–41, 1993
- Kobayashi K, Vogelzang NJ, O’Brien S, Schilsky RL, Ratain MJ. A phase I study of 2-chlorodeoxyadenosine (2-CDA) in solid tumors. Abstract no. PHI-102. Clinical Pharmacology and Therapeutics 53: 232, 1993
- Kurzrock R, Talpaz M, Gutterman JU. Hairy cell leukemia: review of treatment. British Journal of Haematology 79 (Suppl. 1): 17–20, 1991 CrossRef
- Kuttesch JF, Nelson JA. Renal handling of 2′-deoxyadenosine and adenosine in humans and mice. Cancer Chemotherapy and Pharmacology 8: 221–229, 1982 CrossRef
- Kuzel T, Samuelson E, Roenigk H, Torp E, Rosen S. Phase II trial of 2-chlorodeoxyadenosine (2-CDA) for the treatment of mycosis fungoides or the Sezary syndrome (MF/SS). 28th Annual Meeting of the American Society of Clinical Oncology, San Diego, May 17–19, 1992. Abstract no. 1089, p. 272. Proceedings of the American Society of Clinical Oncology, 1992
- Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani PL, et al. 2-Chlorodeoxyadenosine in the treatment of patients with hairy cell leukemia. Abstract no. 36. International Society of Hematology 24th Congress, 23–27 August, 1992
- Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Research 51:5570–5572,1991
- Liliemark J, Pettersson B, Juliusson G. The relationship between plasma 2-chloro-2′-deoxyadenosine (CdA) and cellular CdA nucleotides (CdAN) after intermittent and continuous I.V. infusion in patients with chronic lymphocytic leukemia. Abstract no. 122. Blood 78 (Suppl. 1): 33a, 1991
- Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine (CdA) in cerebrospinal fluid (CSF). Abstract no. 1874. Blood 80 (Suppl. 1): 471a, 1992
- Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology 10: 1514–1518, 1992
- Lill MCC, Golde DW. Treatment of hairy cell leukemia. Blood Reviews 4: 238–244, 1990 CrossRef
- Lipera W. Hairy cell leukaemia. Letter. New England Journal of Medicine 317: 901, 1987 CrossRef
- Nagourney RA, Evans SS, Messenger JC, Zhuang Su Y, Weisenthal LM. 2 Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. British Journal of Cancer 67:10–14, 1993 CrossRef
- Niesvizky R, Siegel D, Michaeli J. 2-Chlorodeoxyadenosine for multiple myeloma. Letter. Blood 81: 868, 1993
- Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute-sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 49: 2112–2135, 1982 CrossRef
- Parker WB, Bapat AR, Shen J-X, Townsend AJ, Cheng Y-C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Molecular Pharmacology 34: 485–491, 1988
- Parsons DG, Bowman EPW, Blakley RL. Selective toxicity of deoxyadenosine analogues in human melanoma cell lines. Biochemical Pharmacology 35: 4025–4029, 1986 CrossRef
- Petzer AL, Bilgeri R, Zilian U, Huan M, Geisen FH, et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 78: 2583–2587, 1991
- Platanias LC, Ratain MJ. Hairy cell leukaemia: the role of alpha interferon. European Journal of Cancer 27 (Suppl. 4): S53–S57, 1991
- Piro LD. 2-Chlorodeoxyadenosine treatment of lymphoid malignancies. Blood 79: 843–845, 1992
- Piro LD. Clinical applications of 2-chlorodeoxyadenosine. American Society of Clinical Oncology. Educational Book, 29th Annual Meeting, Orlando, USA, May 16–18, p. 9–24, 1993
- Piro LD, Miller WE, Carrera CJ, Carson DA, Beutler E. Hairy-cell leukemia. Correspondence. New England Journal of Medicine 317:901,1987 CrossRef
- Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions on hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New England Journal of Medicine 322: 1117–1121, 1990 CrossRef
- Piro LD, Saven A, Ellison D, Thurston D, Carrera CJ, et al. Prolonged complete remissions following 2-chlorodeoxyadenosine (2-CdA) in hairy cell leukemia (HCL). Abstract no. 846, p. 119. Proceedings of the American Society of Clinical Oncology 1992
- Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacology and Therapeutics 49: 239–268, 1991 CrossRef
- Polliack A. A handbook of essential drugs and regimens in hematological oncology. Harwood Academic Publishers, Chur, Switzerland, 1991
- Robertson LE, Chubb S, Meyn RE, Story M, Ford R, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 81: 143–150, 1993
- Ross SR, McTavish D Faulds D. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. Drugs 45: 737–759, 1993 CrossRef
- Santana VM, Mirro Jr J, Harwood FC, Cherrie J, Schell M, et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. Journal of Clinical Oncology 9: 416–422, 1991
- Santana VM, Mirro Jr J, Kearns C, Schell MJ, Crom W, et al. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. Journal of Clinical Oncology 10: 364–370, 1992a
- Santana VM, Hurwitz C, Blakley RL, Krance R. 2-Chlorodeoxyadenosine (2-CDA) induces complete remission of newly diagnosed childhood acute myeloid leukemia (AML). Abstract no. 1428. Blood 80 (Suppl. 1): 360, 1992sb
- Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia and Lymphoma (Suppl.): 133–138, 1991
- Saven A, Piro LD. Treatment of hairy cell leukemia. Blood 79: 1111–1120, 1992
- Saven A, Piro LD. Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Annals of Internal Medicine 119: 278–283, 1993
- Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T cell lymphoma. Blood 80: 587–592, 1992a
- Saven A, Figueroa ML, Piro LD, Beutler E. Complete hematological remissions in chronic myelogenous leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). 28th Annual Meeting of the American Society of Clinical Oncology, San Diego, May 17–19, 1992. Abstract no. 855, pp. 261. Proceedings of the American Society of Clinical Oncology, 1992b
- Saven A, Kawasaki H, Carrera CJ, Waltz T, Copeland B, et al. 2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies. Journal of Clinical Oncology 11: 671–678, 1993a
- Saven A, Figueroa ML, Piro LD, Rosenblatt JD. 2-Chlorodeoxyadenosine to treat refractory histiocytosis X. New England Journal of Medicine 329: 734–735, 1993b CrossRef
- Saven A, Lemon RH, Piro LD. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New England Journal of Medicine 328: 812–813, 1993c CrossRef
- Saven A, Lemon R, Figueroa M, Kosty M, Ellison D, et al. Complete hematologic remissions in stable phase, Ph-chromosome positive, chronic myeloid leukemia (CML) following 2-chlorodeoxyadenosine (2-CdA). Abstract no. 1022, p. 310. Proceedings of the American Society of Clinical Oncology, 1993d
- Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. Journal of Clinical Investigation 75: 377–383, 1985 CrossRef
- Seto S, Carrera CJ, Wasson DB, Carson DA. Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes. Advances in Experimental Medicine and Biology 195 (pt. B): 577–582, 1986
- Seto S, Carrera CJ, Wasson DB, Carson DA. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. Journal of Immunology 136: 2839–2843, 1986
- Sorensen JM, Vena DA, Montello MJ, Christian MC, Cheson BD. Treatment of hairy cell leukemia (HCL) with 2-chlorodeoxyadenosine (CDA) under the group protocol mechanism. 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, May 16–18, 1993. Abstract no. 988, p. 302. Proceedings of the American Society of Clinical Oncology, 1993
- Spielberger RT, Golomb HM. Hairy cell leukemia 1992. Leukemia 6 (Suppl. 4): 142–146, 1992
- Spielberger RT, O’Brien S, Ratain MJ, Williams SF, Larson RA. Phase I study of 2-chlorodeoxyadenosine in hematologic malignancies. Abstract no. 1831. Blood 80 (Suppl. 1): 460a, 1992
- Spielberger RT, Larson RA, O’Brien SM, Williams SF, Ratain MJ. Phase I study of 2-chlorodeoxyadenosine (CdA) by 1 hour bolus infusion in hematologic malignancies. 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, May 16–18, 1993. Abstract no. 359, p. 140. Proceedings of the American Society of Clinical Oncology, 1993a
- Spielberger RT, Stock W, Larson RA. Listeriosis after 2-chlorodeoxyadenosine treatment. New England Journal of Medicine 328: 813–814, 1993b CrossRef
- Talbot DC, Orr RM, Serafinowski P, Harrap KR. Characterisation of acquired resistance to 2-chloro-2′deoxyadenosine in lymphoid cell lines. 84th Annual Meeting of the American Association for Cancer Research, Orlando, May 19–22, 1993. Abstract no. 1816, p. 305. Proceedings of the American Association for Cancer Research, 1993
- Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 80: 2203–2209, 1992a
- Tallman M, Hakimian D, Koslow D, Variakojis D, Snower D, et al. Antiproliferative activity of 2-chlorodeoxyadenosine (2-CDA) in resistant lymphoid malignancies. Abstract no. 898, p. 272. Proceedings of the American Society of Clinical Oncology 11, March 1992b
- Tefferi A, Phyliky RL. A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities. Mayo Clinic Proceedings 67: 457–461, 1992
- Urba WJ, Longo DL. Lymphocytic lymphomas: clinical course and management. In Moossa et al. (Eds) Comprehensive Textbook of Oncology, Vol. 2, pp. 1277–1295, Williams & Wilkins, Baltimore, 1991
- Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, et al. Deoxy-coformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 73: 38–46, 1989
- Vahdat Jr L, Warrell RP. Treatment of acute myeloblastic leukemia in adults with 2-chloro-deoxyadenosine. 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, May 16–18, 1993. Abstract no. 991, p. 302. Proceedings of the American Society of Clinical Oncology, 1993
- Wataya Y, Hirota Y, Hiramoto-Yoshioka A, Tanaka S, Otani T, et al. The mechanism of 2-chlorodeoxyadenosine-induced cell death. Advances in Experimental Medicine and Biology 253B: 227–234, 1989 CrossRef
- Weiss G, Kuhn J, Irvin R, Hardy J, Mooneyham T, et al. Phase I trial of 2-chlorodeoxyadenosine (2-CDA) by 120-hour infusion for solid cancers. 29th Annual Meeting of the American Society of Clinical Oncology, Orlando, May 16–18, 1993. Abstract no. 455, p. 164. Proceedings of the American Society of Clinical Oncology, 1993
Volume 46, Issue 5 , pp 872-894
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors